The business combination is expected to be accretive to Cigna earnings per share in the first full year of operations. The agreement has been approved by the boards of directors of both companies and is subject to required regulatory approvals. Consistent with its strategy, CI expects to continue to create meaningful near-term earnings growth and expects this transaction to enhance its revenue growth and profitability over time.






